Clinical Trial Update: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase III trial is comparing HB0025 plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment of advanced squamous non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• HB0025
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. | Conditions: Squamous Non-small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING